Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

The current study was conducted to evaluate the safety and biological activity of dual inhibition of the vascular endothelial growth factor (VEGF) pathway with combined bevacizumab and cediranib (a VEGF receptor tyrosine kinase inhibitor).

[1]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[2]  E. Van Cutsem,et al.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Sikora,et al.  Tumor-Expressed Inducible Nitric Oxide Synthase Controls Induction of Functional Myeloid-Derived Suppressor Cells through Modulation of Vascular Endothelial Growth Factor Release , 2012, The Journal of Immunology.

[4]  L. Deangelis,et al.  Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Michael Koutsilieris,et al.  Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis , 2011, BMC Cancer.

[6]  Howard I. Scher,et al.  Circulating Tumor Cells as Biomarkers in Prostate Cancer , 2011, Clinical Cancer Research.

[7]  A. Ørbo,et al.  Expression of iNOS--a favourable prognostic marker for early-stage carcinoma of the uterine cervix. , 2011, Anticancer research.

[8]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[9]  G. J. M. Parker,et al.  A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics , 2011, Cancer Chemotherapy and Pharmacology.

[10]  A. Harris,et al.  Biomarkers to predict the clinical efficacy of bevacizumab in cancer. , 2010, The Lancet. Oncology.

[11]  S. Sarda,et al.  In Vitro Hepatic Metabolism of Cediranib, a Potent Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor: Interspecies Comparison and Human Enzymology , 2010, Drug Metabolism and Disposition.

[12]  Thomas Benner,et al.  Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Loda,et al.  Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer , 2010, British Journal of Cancer.

[14]  M. Koch,et al.  Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. , 2010, Gastroenterology.

[15]  D. Hong,et al.  Abstract 2687: Development of a new, highly sensitive assay for circulating tumor cell (CTC) detection based on the CellSearch® CTC Profile Kit enrichment and laser scanning cytometry analysis , 2010 .

[16]  J. Schellens,et al.  Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  I. Judson,et al.  Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Murakami,et al.  Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors , 2009, Cancer Chemotherapy and Pharmacology.

[19]  R. Motzer,et al.  Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Loibl,et al.  VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection , 2009, Journal of Clinical Pathology.

[21]  E. Grimm,et al.  Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. , 2008, Nitric oxide : biology and chemistry.

[22]  F. Penault-Llorca,et al.  Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. , 2008, European journal of cancer.

[23]  Lori Minasian,et al.  Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Douglas B. Evans,et al.  Cancer-associated stromal fibroblasts promote pancreatic tumor progression. , 2008, Cancer research.

[25]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[26]  J. Drevs,et al.  Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Dahut,et al.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[29]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[30]  L. Ellis,et al.  The role of nitric oxide in mediating tumour blood flow , 2006, Expert opinion on therapeutic targets.

[31]  D. Wink,et al.  The biphasic nature of nitric oxide responses in tumor biology. , 2006, Antioxidants & redox signaling.

[32]  L. Broemeling,et al.  Tumor iNOS predicts poor survival for stage III melanoma patients , 2006, International journal of cancer.

[33]  Alessandro Ambrosi,et al.  The Prognostic Value of Circulating Tumor Cells in Patients with Melanoma: A Systematic Review and Meta-analysis , 2006, Clinical Cancer Research.

[34]  R. Jain,et al.  The role of nitric oxide in tumour progression , 2006, Nature Reviews Cancer.

[35]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Barry,et al.  AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. , 2005, Cancer research.

[37]  岩崎 順子,et al.  Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer.Hurwitz H,et al.N Engl J Med 2004;350:2335-42.PMID:15175435--大腸癌に対する分子標的治療の有用性を証明したきわめて重要な第3相試験 , 2004 .

[38]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[39]  A. Tarnawski,et al.  Dual actions of nitric oxide on angiogenesis: possible roles of PKC, ERK, and AP-1. , 2004, Biochemical and biophysical research communications.

[40]  Weiming Xu,et al.  The role of nitric oxide in cancer , 2002, Cell Research.

[41]  J. Liao,et al.  Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. , 2001, Cancer research.

[42]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[43]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[44]  D G Altman,et al.  Survival probabilities (the Kaplan-Meier method) , 1998, BMJ.

[45]  R. Lodato,et al.  Inhibition of Interleukin-1-α-Induced Nitric Oxide Synthase in Vascular Smooth Muscle and Full Reversal of Interleukin-1-α-Induced Hypotension by Nω-Amino-L-arginine , 1992 .

[46]  J. Adams,et al.  Inhibition of interleukin-1-alpha-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-1-alpha-induced hypotension by N omega-amino-L-arginine. , 1992, Journal of the National Cancer Institute.

[47]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.